BLOOD TRANSFUSION REQUIREMENTS AND FILTER LONGEVITY WITH REGIONAL CITRATE ANTICOAGULATION COMPARED WITH HEPARIN by E Burford et al.
POSTER PRESENTATION Open Access
Blood transfusion requirements and filter
longevity with regional citrate anticoagulation
compared with heparin
E Burford, E Walter, A Beverly*
From ESICM LIVES 2015
Berlin, Germany. 3-7 October 2015
Introduction
Citrate is the recommended anticoagulant for continu-
ous renal replacement therapy (RRT) [1], and is
thought to confer numerous benefits, including more
continuous hours of filtration, fewer total circuits used,
less overall cost and maybe improved patient and kid-
ney survival when compared with heparin anticoagula-
tion [2]. Our ICU changed from heparin to citrate
anticoagulation in June 2014. Our unit uses a transfu-
sion trigger of 7g/dl [3] unless the clinical situation
dictates otherwise.
Objectives
This observational study is to investigate blood transfu-
sion requirements and haemofilter set life before and
after the change from systemic heparin to citrate regio-
nal anticoagulation, to add to growing international evi-
dence, and to inform local practice.
Methods
Data were collected on set life and the number of blood
transfusions patients received during the period of filtra-
tion, and in the 24 hours afterwards. Data on patients
anticoagulated with heparin were collected retrospec-
tively up until the day of changing to citrate. Data dur-
ing citrate anticoagulation were collected prospectively,
from the day of changing, onwards.
Results
6 months of filtration with heparin and 3 months of
citrate were observed. 97 patients required RRT (65
with heparin, 28 with citrate, 4 with both), for a total of
556 days. Table one shows the comparison between
heparin and citrate. There was no difference in the aver-
age duration of filtration required between the 2 sys-
tems. Filter life increased from 0.86 days with heparin,
to 1.55 days with citrate (p = 0.007 by Student t-test).
The number of transfusions required fell from 0.33
units per day with heparin, to 0.25 units per day with
citrate (p > 0.05).
Conclusions
Regional citrate anticoagulation increases filter life
when compared with systemic heparinisation, with sig-
nificant cost and other savings. There is a non-signifi-
cant trend towards a reduction in blood transfusion
requirements.
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Table 1 Comparison of citrate with heparin
anticoagulation.
Heparin Citrate
Renal days 357 199
Median renal days per patient episode 3 3
Number of filters used 408 128
Total filter cost (•) 32807.28 10292.48
Renal days per filter 0.86 1.55
Filter cost per renal day (•) 91.89 51.72
Blood transfusions per day 0.33 0.25
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